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Background: Schistosomiasis is responsible for a tremendous public health burden, yet only a single drug,
praziquantel, is available. New antischistosomal treatments should therefore be developed. The accuracy, speed and
objectivity of in vitro drug screening depend on the assay read-out. Microscopy is still the current gold standard
and is in need of updating to an automated format. The aim of the present study was to investigate a panel of
fluorescence/luminescence dyes for their applicability as viability markers in drug sensitivity assays for Schistosoma
mansoni schistosomula.
Methods: A search for available viability and cytotoxicity marker assays and dyes was carried out and a short-list of
the most interesting candidates was created. The selected kits and dyes were tested on S. mansoni Newly
Transformed Schistosomula (NTS), first to assess whether they correlate with parasite viability, with comparatively
low background noise, and to optimise assay conditions. Markers fulfilling these criteria were then tested in a
dose–response drug assay using standard and experimental drugs and those for which an IC50 value could be
accurately and reproducibly calculated were also tested on a subset of a compound library to determine their
hit-identification accuracy.
Results: Of the 11 markers selected for testing, resazurin, Vybrant® and CellTiter-Glo® correlated best with NTS
viability, produced signals ≥ 3-fold stronger than background noise and revealed a significant signal-to-NTS
concentration relationship. Of these, CellTiter-Glo® could be used to accurately determine IC50 values for
antischistosomals. Use of CellTiter-Glo® in a compound subset screen identified 100 % of hits that were identified
using standard microscopic evaluation.
Conclusion: This study presents a comprehensive overview of the utility of colorimetric markers in drug screening.
Our study demonstrates that it is difficult to develop a simple, cheap “just add” colorimetric marker-based drug
assay for the larval stage of S. mansoni. CellTiter-Glo® can likely be used for endpoint go/no go screens and
potentially for drug dose–response studies.
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Schistosomiasis, causing 3.3 million DALYs lost, is one
of the most important Neglected Tropical Diseases
(NTDs) [1]. It is a water-borne trematodiasis caused by
any of six Schistosoma species that parasitise humans:
Schistosoma haematobium, S. mansoni, S. japonicum,
S. mekongi, S. guineensis and S. intercalatum- the former
3 being most common [2, 3]. Schistosomiasis is prevalent
mainly in rural areas of poor sanitation, with the majority
of cases occurring in Sub-Saharan Africa [3, 4]. The bot-
tom line of the WHO schistosomiasis control programme
is morbidity reduction via preventative chemotherapy [3].
Only a single drug- praziquantel- is used to treat millions
of people annually and its coverage is projected to reach
235 million people by 2018, which raises concerns of in-
creasing drug pressure [5, 6]. Moreover, although prazi-
quantel is a safe and cheap therapy effective on the adult
stage of the disease, it is inactive against the juvenile stage
[6, 7]. Therefore, new chemotherapies are desperately
needed.
In the past, standard operating procedures (e.g. estab-
lished at TDR-designated compound screening centers)
relied on adult worms incubated with the candidate
drugs for 72 hours, after which their viability is assessed
microscopically [8]. This method requires the intensive
use of mice (as no in vitro life cycles currently exist), is
time consuming and low-throughput. Thus recently, the
use of Newly Transformed Schistosomula (NTS) has
been popularised as a higher-throughput screen [9–12].
Nonetheless, assessing parasite viability via microscopic
read-out is slow and subjective and is therefore a bottle-
neck for high-throughput screening. Consequently, with
recent advancements in automated technologies, a num-
ber of assay read-out alternatives have been attempted
with varying degrees of success [9]. These methods in-
clude the measurement of parasite mobility over time
via electrical impedence with xCELLigence [13], isother-
mal microcalorimetry [14] and automated image-based
Bayesian classification [15]. On the other hand, using dye-
based assays that can be read by an automatic plate reader
would be a simpler, cheaper, more practical and more
trainable read-out alternative, requiring little extra equip-
ment or software. Three fluorescent and one luminescent
assay reagent have been studied on S. mansoni NTS to
date: the Alamar Blue® viability assay (resazurin), the fluor-
escein diacetate/ propidium iodide fluorescent multiplex
assay and a fluorometric L-lactate assay (fluorescent) and
CellTiter-Glo® (luciferase) as the luminescent assay. In
more detail, Alamar Blue® could discriminate between live
and dead NTS after 7 days of incubation with standard
drugs but not for earlier time-points and it could not be
used to measure dose–response drug effects [11]. The
fluorescein diacetate/ propidium iodide assay is a duplex
viability and cytoxicity assay where fluorescein diacetatestains live NTS and propidium iodide stains dead NTS
[16]. This assay was successful in that it could be used to
calculate an LD50 value for auranofin, an antirheumatic
agent that is active against S. mansoni, and could distin-
guish between dead and alive NTS for several standard
drugs. However, practical issues, such as the requirement
of a rinsing step and the need for a high number of NTS,
as well as its questionable ability to determine dose-
dependent effects for all standard drugs, were elements
that could be improved upon. Howe and colleagues inves-
tigated lactate, a byproduct of glycolysis known to be
secreted via aquaglyceroporins from NTS and adult
worms, as a possible marker for viability. They too were
able to generate dose–response curves for some but not
all standard drugs using a commercial L-lactate kit [17].
Nonetheless, the procedure requires removing the super-
natant from the drug assay (without aspirating the NTS)
and then diluting it to an acceptable fluorescence range as
needed, rendering it less than high-throughput. More re-
cently, Lalli and colleagues (2015) validated the use of the
commercial luminescence-based cell viability kit, CellTiter-
Glo®, in an in vitro assay using S. mansoni NTS and adult
worms [18]. Here, however, a precise multi-drop dispenser
was required to ensure an exact number of NTS was
present in each well. Hence, although the investigation of
marker-dye based assays has been a popular pursuit, the
aim of a simple, inexpensive and precise dye that does not
require much additional equipment or analysis has not en-
tirely been met.
In the present study we sought to identify an easy-to-
use, “just-add” viability or cytotoxicity marker assay that
can accurately determine the viability of NTS in a drug
sensitivity screen. We therefore reviewed the literature
for previous use of dyes and markers on S. mansoni for
their potential use as viability or cytotoxicity markers in
an automated drug assay. We also researched the market
for commercially available viability and cytotoxicity kits
and dyes that could in theory be adapted for use in an
S. mansoni NTS drug assay. Eleven markers, resazurin
(the active component of Alamar Blue®), OmniCathep-
sin™, CellTiter-Glo®, Vybrant®, CytoTox- ONE™, LIVE/
DEAD® viability/cytotoxicity kit-, ApoTox-Glo™, Cell-
Tox™ Green Cytotoxicity Assay, DAPI, Hoechst 33258
(bis-Benzimide) and FluoForte® Calcium Assay with
diverse modes of action were selected. All markers were
tested to elucidate whether wells containing NTS could
produce signals significantly stronger than wells contain-
ing medium only, a significant signal-to-NTS concentra-
tion relationship and if differential signals between live
and dead NTS could be observed. For the three markers
resazurin, Vybrant® and CellTiter-Glo® meeting this cri-
teria, dose–response drug assays were conducted.
CellTiter-Glo® was further validated on a 25-compound
subset of a compound library of FDA-approved drugs.
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Literature search
A recent review on approaches to measuring helminth
viability [9] served as a starting point to investigate dyes
and methods that had already been attempted to meas-
ure S. mansoni viability. Each marker listed in the publi-
cation was checked to see how it was used on
S. mansoni. Specifically, we looked if the named marker
had already been used on NTS in a multi-well assay. In
parallel, a simple Google and PubMed search was con-
ducted in order to identify commercial viability/cytotox-
icity kits available on the market or markers and dyes
that are not normally used to measure viability but could
be used to measure S. mansoni viability in theory. Terms
used were “colorimetric viability markers”, “colorimetric
viability assays”, “viability assays”, “fluorescent viability
markers”, “cytotoxicity assays”, “cytotoxicity marker as-
says”, “Schistosoma mansoni cytotoxicity”, “Schistosoma
mansoni viability” and “Schistosoma mansoni assay”.
With the aim of identifying desirable candidate markers
for NTS, the following primary exclusion criteria were
applied: (i) active component should not be one that has
already been identified as ineffective at measuring viabil-
ity in NTS (based on published or unpublished data); (ii)
must not rely on cellular replication since NTS do not
replicate or grow very fast; (iii) must not require add-
itional rinsing steps since NTS do not fix to the bottom
of well plates. In addition, it was desirable that the
marker did not also measure bacteria and fungi viability
and would not be too costly.
Media, chemicals and drugs
Medium 199 was purchased from Gibco (Basel,
Switzerland), inactivated foetal calf serum (iFCS) was ob-
tained from Connectorate AG (Dietikon, Switzerland)
and a mixture of penicillin-streptomycin (10,000 units/
ml penicillin and 10 mg/ml streptomycin) was pur-
chased from Sigma-Aldrich (Buchs, Switzerland).
CellTiter-Glo®, ApoTox-Glo™, CellTox™ Green Cytotox-
icity Assay and CytoTox-ONE™ were purchased from
Promega. The Vybrant® Cytotoxicity Assay Kit and the
LIVE/DEAD® Viability/Cytotoxicity Kit for mammalian
cells were purchased from Molecular Probes (Invitrogen),
whereas FluoForte® Calcium Assay kit was acquired from
Enzo Life Sciences Inc. DAPI (4’, 6-Diamidino-2-phenylin-
dole dihydrochloride) and Hoechst 33258 were purchased
from Sigma-Aldrich and stock solutions of 5 mg/ml were
constituted by dissolving the substrate in dH2O and
DMSO respectively. The OmniCathepsin™ reagent was
prepared by dissolving OmniCathepsin™ substrate (Enzo
Life Sciences) in DMSO solution at a concentration of
10 mM. The resazurin dye was constituted by dissolving
resazurin sodium salt (Sigma) in 1x PBS solution at a con-
centration of 125 mg/l. All markers were stored at –20 °Cuntil use except DAPI and Hoechst 33258, which were
stored at 4 °C.
Praziquantel, and mefloquine were purchased from
Sigma-Aldrich (Buchs, Switzerland), and oxamniquine
was donated by Dr. Quentin Bickle. Drug stock solutions
were made by dissolving the compounds in DMSO
(dimethyl sulfoxide, Fluka, Buchs, Switzerland) at a con-
centration of 10 mM and were stored at −20 °C until
use.
Transformation of S. mansoni cercariae into Newly
Transformed Schistosomula (NTS)
For the transformation of cercariae into schistosomula, a
cercarial suspension was collected from S. mansoni-infected
Biomphalaria glabrata snails and subjected to a mechan-
ical in vitro transformation described previously [12].
The NTS were then placed in warm culture medium:
Medium 199 supplemented with 5 % iFCS and 1 %
penicillin-streptomycin mixture and incubated for 24 hours
at 37° C and 5 % CO2 until use.
Signal correlation to NTS concentration assays and
exposure time assays
Assays were set up to measure whether incubation with
the selected marker yielded a significant 3:1 signal-to-
background (S/B) ratio. In addition, viability markers
should present a linear curve between the signal (fluor-
escence or luminescence) and increasing concentrations
of live NTS, but a poor signal and no relationship when
incubated with dead NTS and vice-versa when cytotox-
icity markers are used. Thus for each marker, an assay
with increasing concentrations of NTS/well (20, 40, 60,
80, 100, 200, 300 and 400 NTS/well), of live and dead
NTS was set up. To measure signal strength in correl-
ation to exposure time to the marker, the NTS concen-
tration assays were measured at multiple time-points
(Additional file 1: Table S1). In addition, because it was
noted for Cell-Tox™ Green that it mattered for signal in-
tensity how NTS were killed, a variety of substances
were tested to kill the NTS for the potential cytotoxicity
markers, the FluoForte® Calcium Assay, DAPI and
Hoechst 33258 (Additional file 1: Table S1).
The total well volume, including the marker, was between
100 and 250 μl. Control wells contained culture medium
only (supplemented Medium 199). Altogether, 2 to 3 trials
of duplicates/triplicates were performed for each marker.
Marker-specific methods (the amount of marker added, the
plate incubation times and the excitation/emission (Ex/
Em)) are summarised in Additional file 1: Table S1. Spectra
were determined by the commercially published protocols
or in the case of resazurin, Hoechst 33258 and DAPI, from
previous publications [11, 19–21]. Luminescence or fluor-
escence was read using the SpectraMax® M2 Multi-Mode
Microplate Reader (Molecular Devices).
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determine the optimal concentration of the dye. LIVE/
DEAD® and ApoTox-Glo™ are duplex assays, and thus the
plates were scanned twice, each time at the Ex/Em spectra
specified for each dye (Additional file 1: Table S1).
Since LIVE/DEAD®, CellTox™ Green Cytotoxicity,
DAPI and Hoechst 33258 are fluorescence markers that
stain components within the NTS themselves, read-outs
were complemented by confirmation of NTS staining
via fluorescence microscopy. From the assay, 20 μl of
live and dead NTS suspensions were placed on glass
slides with cover slips. Inspection was conducted using
the Leica DM5000B upright microscope. The L5 filter
was used to view objects stained by calcein from the
LIVE/DEAD® kit and CellTox™ Green Cytotoxicity Assay
cyanine dye; the Texas Red (TR) filter was used to view
objects stained by EthD-1. The CY3 filter was used for
DAPI and the A4 filter for Hoechst 33258. Imaging was
possible via the microscope camera, which was con-
nected to Leica Application Suite 2.4.0 imaging software.
Drug sensitivity assay
Markers that showed an S/B of 3:1 and a strong signal-
to-NTS concentration relationship were selected for
testing with two standard and one experimental drug to
assess if they could be used to determine IC50 values in
a dose–response drug sensitivity assay. Drugs were seri-
ally diluted to fit a range of previously reported IC50
values [22, 23]. The dilution series were as follows: 20,
10, 5, 2.5, 1.3 and 0.7 μM for praziquantel and meflo-
quine; and 240, 120, 60, 30, 15, 7.5 and 3.7 μM for
oxamniquine.
The drug assays were set up according to manufac-
turer protocols using 200 NTS and an incubation time
of 24 hours with resazurin, 15 min with Cell-Titer-Glo®
and 70 min with Vybrant®. Assays were evaluated at vari-
ous time-points. Each SpectraMax® read-out was accom-
panied by a microscopic read-out in order to compare
the two methods. Microscopic assessment of viability
was done by observing the NTS morphology and motil-
ity and by assigning the NTS viability scores as follows:
0 = dead; 1 = both slower movement and damage to
tegument or severely impaired movement or severely
damaged tegument; 2 = slow movement or notable dam-
age to tegument; 3 = lively movement and undamaged
tegument. IC50 values, which describe the drug concen-
tration at which worm viability is inhibited by 50 % as
scored by the viability scare, were calculated as described
below using both read-outs and compared.
Assay validation
To confirm that CellTiter-Glo® could be reliably used in
a drug screen, a subset (n = 25) of a previously screened
library of FDA approved compounds [24] was chosenfor re-screening with CellTiter-Glo®. Compounds were
selected by randomly picking from the “hit” and “not
hit” lists, such that the hit rate in the assay would be
~20-25 %. The compounds were screened on NTS at
10 μM and CellTiter-Glo® was added as previously de-
scribed. Each compound was tested in duplicate twice,
along with an NTS-free blank for background measure-
ment. Assays were assessed by both a microscopic evalu-
ation and the SpectraMax® scan. Hit compounds were
defined as those compounds that achieved ≥ 75 % reduc-
tion in viability (calculated using the viability score de-
scribed above) for the microscopic evaluation and ≥ 75 %
reduction in fluorescence signal relative to live controls.
Dead controls were included in the assay to calculate the
Z’ factor for each plate.
Statistical analysis
Averages, standard deviations and S/B ratios were calcu-
lated and graphs generated with Microsoft Office Excel
2013. Dose–response drug sensitivity assays using the
markers were read both by the SpectraMax® and manu-
ally via microscopic read-out. From the SpectraMax®
read-outs, the IC50 values were calculated in SoftMax®
Pro. From the microscopic read-out, the IC50 values
were calculated with the help of CompuSyn® (2006). The
Z’ factor was calculated according to the formula de-
scribed by Zhang et al., where a score ≥ 0.5 is considered
excellent [25].
Results
Literature search
A substantial number of dyes have been tested on the dif-
ferent stages of S. mansoni and many of them specifically
on the NTS stage (Additional file 2: Table S2). Many dyes,
however, were not suitable for automated drug sensitivity
assay read-outs, the reasons for which are presented in
Additional file 2. Our search identified 2 viability, 3
cytotoxicity, 2 multiplex and 4 “experimental” markers for
further testing. Their features/mechanism of action are
summarised in Additional file 2: Table S2.
Signal to NTS concentration assays and exposure time
assays
Viability markers
For all assays, optimal incubation parameters and key re-
sults are summarised in Table 1.
CellTiter-Glo® assay results showed a strong correl-
ation between live NTS number and luminescence signal
(R2 = 0.98) (Fig. 1a). The signals were strongest at
15 min incubation time with the reagent, after which the
signal strength decreased. A S/B ratio of at least 3:1 was
observed from 100 or more NTS/well. Dead NTS did
yield a luminescence signal but comparable to that of
the background luminescence.
Table 1 Summary of marker optimizations and results
Marker Type Marker Assay Optimal
incubation time
S:B ratio≥ 3:1? Correlation to NTS
viability/cytotoxicity
Selected for
drug assay
testing?
Justification
Viability
Markers
CellTiter-Glo® 15 min Yes, with ≥ 100
NTS
Strong Yes Met criteria
Resazurin 24 hours Yes, with ≥ 200
NTS
Strong Yes Met criteria
Cytotoxicity
Markers
Vybrant® 70 min Almost, with ≥
300 NTS
Strong up to 300 NTS Yes Met criteria
CytoTox-ONE 2 hours No Strong No S:B ratio low, large standard deviations
between data points
CellTox™ Green
Cytotoxicity
Assay
24 hours Yes, with ≥ 400
NTS
Strong with≥ 400
NTS
No Viable NTS died within 24 hours of
exposure to dye; strong signals from
completely lysed cells only
Multiplex
Markers
LIVE/DEAD®
Viability/
Cytotoxicity Kit
Does not exist No Poor for both live
and dead NTS
No Poor correlation to NTS viability/
cytotoxicity
ApoTox-Glo™ Does not exist No Strong for live-cell
marker, poor for
dead-cell marker
No Markers induced spazzing and death of
NTS after 6 hours
Experimental
Markers
OmniCathepsin™ 2 hours (with
10 μM marker
concentration)
No Good: Differential
signals for live vs.
dead observed
No S:B ratio too low, not enough difference
between live and dead NTS
FluoForte®
Calcium Assay
1.5 hours with≥
200 dead NTS
Yes, with ≥ 200
dead NTS
(lysed only)
Poor: strong staining
for completely lysed
cells only
No Stains only completely lysed cells
DAPI 15 min (with
10 μg/ml dye
concentration)
No Good: stained many
dead NTS phenotypes
No Background fluorescence too high,
signals too low
Hoechst 33258 15 min (with
1 μg/ml dye
concentration)
No Good: stained many
dead NTS phenotypes
No Background fluorescence too high,
signals too low
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live NTS concentration (R2 = 0.98) but revealed large
standard deviations (Fig. 1b). The signals, S/B ratio and
R-squared values were highest after 24 hours of incuba-
tion. The minimum number of live NTS that gave at
least a 3:1 S/B ratio was 200 NTS. The fluorescence sig-
nal for dead NTS was low (183.6 ± 40.3 RFU at 300 dead
NTS when subtracted from background) and there was
not a strong correlation between number of dead NTS
and the fluorescence signal (R2 = 0.003).
Cytotoxicity markers
Dead NTS incubated with Vybrant® yielded a strong
signal-to-dead-NTS concentration correlation up to 300
dead NTS (R2 = 0.95), after which the signal plateaued.
The highest S/B ratio was obtained after 70 min with
300 dead NTS per well (S/B = 2.78:1), though this fell
just below the 3:1 cut-off. The signals for live NTS were
comparable to background levels (Fig. 2a).
A strong correlation between dead NTS concentration
and fluorescence signal (R2 = 0.97) was observed for
CytoTox-ONE™, however, with very large standard de-
viations for each data point. Live NTS signals werecomparable to background levels but background
levels for CytoTox-ONE™ were very large (6605 RFU)
(Fig. 2b). As a result, the S/B ratio was always at
around 1:1 regardless of dead NTS concentration or
exposure time to CytoTox-ONE™.
CellTox™ Green showed a linear relationship between
fluorescence and number of dead NTS per well, exhibit-
ing a significant signal at a concentration from 400 NTS
and onwards at 24 hours (Fig. 2c). Fluorescence micros-
copy after 4 hours incubation with the marker showed
that the dye was effectively penetrating the cell
Additional file 3: Figure S1(E, F), though the signal
intensity and relationship linearity measures are signifi-
cant from 24 hours after addition of reagent (S/B >3:1).
Additionally, live NTS measured by this reagent gave
low fluorescence signals (S/B <2:1). However, after
24 hours of exposure to CellTox™ Green, live NTS via-
bility was severely diminished and hence could not be
used as reliable controls at this time-point measurement.
An important point is that only lysed NTS, and not
heat, EtOH 10 %, DMSO 25 %, praziquantel nor mef-
loquine – killed NTS, showed significant values com-
pared with the control wells.
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Fig. 1 Correlation to NTS concentration for viability markers a CellTiter-Glo® and b resazurin. Green lines represent data from live NTS and red
lines represent data from dead NTS. The dotted line represents the background signal from medium-only wells. Curves are shown for the optimal
incubation time for each marker: 15 min for Cell-Titer Glo and 24 hours for resazurin.
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Using the LIVE/DEAD® Viability/Cytotoxicity Kit, mea-
surements with calcein showed weak signals and a poor
correlation with live NTS concentration (Fig. 3a). How-
ever, microscopic images demonstrate that at 45 minutes
after exposure to the dyes, the NTS are stained properly
and discriminately (Additional file 3: Figure S1(A-D)).
Additionally, signals from dead control NTS were very
close to the range of the live NTS signals. Meanwhile,
signals generated from dead NTS scanned by the EthD-
1 Ex/Em spectra yielded an extremely low signal and
only a moderate linear correlation (Fig. 3b). The negative
controls, however, also showed poor signals and linear-
ity. Measurements with calcein using as many as 1000
NTS showed an improved signal correlation with NTS
numbers (R2 = 0.89 at 4 hours incubation time) but
nonetheless a low fluorescence signal overall (Additional
file 4: Figure S2(A)). Measurements with EthD-1 showed
no significant improvement in signal and the signal even
plateaued at higher NTS concentrations (Additional file 4:
Figure S2(B)). The S/B ratio was less than 3 for both
calcein and EthD-1 at all time-points.ApoTox-Glo™ also presented as a poor multiplex assay.
The AFC reagent yielded a strong linear relationship with
live NTS concentrations and high signal levels (Fig. 3c) but
only after 6 hours of exposure to the marker, when micro-
scopic evaluation revealed spastic NTS. By 24 hours, all
NTS were dead. The bis-AAF-R110 reagent yielded a very
poor signal and NTS concentration correlation with dead
NTS (Fig. 3d). Paradoxically, the signal correlation to in-
creasing live NTS concentrations was strong (R2 = 0.99).
Experimental reagents
As the experimental dyes selected for this work have not
yet been used as viability or cytotoxicity markers, no stand-
ard protocol for reagent concentration or suggested reagent
exposure time existed. Hence, initial experiments were
conducted to determine these parameters, summarised in
Table 1. Thereafter, experiments were conducted to deter-
mine if the reagent could produce differential signals for
live versus dead NTS.
Using the OmniCathepsin™ assay, high fluorescence
signals were yielded by live NTS (Fig. 4a). The signals
for live NTS were notably higher than for dead NTS,
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Fig. 2 Correlation to NTS concentration for cytotoxicity markers a Vybrant®, b CytoTox-ONE™ and c CellTox™ Green. Green lines represent data
from live NTS and red lines represent data from dead NTS. The dotted line represents the background signal from medium-only wells. Curves are
shown for the optimal incubation time for each marker: 70 min for Vybrant®, 2 hours for CytoTox-ONE and 24 hours for CellTox™ Green.
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assay, and neither significant differences between live
and dead NTS signals, nor a 3:1 S/B ratio could be
achieved.
Incubation of dead NTS with FluoForte® Calcium
Assay produced significant signal intensity in compari-
son with live NTS (Fig. 4b). However, this was only the
case for completely lysed NTS. NTS killed by heat,
EtOH 10 % or DMSO 25 % did not produce high signals.
Since no drug completely lyses NTS, further investiga-
tions with this assay were discontinued.
For both DAPI and Hoechst 33258, the S/B ratio did
not reach the 3:1 threshold, though a difference was
observed between the fluorescence values of live versus
lysed or mefloquine-killed NTS (Figs 4c and d). When
observed with fluorescence microscopy, both dyes stained
dead NTS at their determined optimal incubation times
and did not stain control live NTS (Additional file 3:
Figure S1(E-J)).
Since high background signals were a notable problem
for many of these stains, assays with Omnicathepsin™,
DAPI and Hoechst 33258 were set up in order to assess
the effect of phenol red, iFCS and medium type on thebackground fluorescence values (Additional file 5: Figure
S3). Indeed, both iFCS and phenol red contribute to high
background noise though most of it is attributable to pres-
ence of iFCS. However, it is not possible for NTS to re-
main viable without iFCS, hence removing it from the
medium or decreasing the concentration are not viable
options for a 72 hour drug assay.
Drug sensitivity assays
Resazurin, Cell-Titer Glo®, and Vybrant® were selected
for further testing in a drug sensitivity assay using stand-
ard drugs. An automatic read-out with resazurin did not
produce dose-dependent fluorescence values and thus
IC50 values could not be calculated (Table 2). Vybrant®
did not yield IC50 values for praziquantel and oxamni-
quine and gave an IC50 for mefloquine that was higher
than microscopically derived values. In the case of
CellTiter-Glo®, an automatic read-out did not produce
sufficient dose-dependent values to calculate an IC50 for
praziquantel. The IC50 calculated for oxamniquine was
higher than the microscopically determined one,
though oxamniquine IC50 values fluctuated widely even
between microscopic read-outs. Nonetheless, the IC50
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Fig. 4 Signals of live and dead NTS over time for a OmniCathepsin™, b FluoForte® Calcium Assay, c DAPI and d Hoechst 33258
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microscopic read-out. Furthermore, a single concentra-
tion (10 μM) drug screen with CellTiter-Glo® revealed
that of the 25 compounds screened, 100 % of positives
were identified as such, and 100 % of negatives were
also identified as such (Table 3). The plate Z’ scores
were ≥ 0.6.
Discussion
Concerns about increasing drug pressure due to the exclu-
sive use of praziquantel underscore the need for new treat-
ments [26]. The growing availability of new technologies,Table 2 IC50 values generated by resazurin, CellTiter-Glo® and Vybra
Resazurin CellTiter-Glo®
Drug IC50 SpectraMax
(μM)
IC50 Microscopic
Readout (μM)
IC50 SpectraMax
(μM)
Praziquantel not calculable 1.7 ± 1.5 not calculable
Mefloquine not calculable 2.6 ± 1.1 4.9 ± 2.9
Oxamniquine not calculable 135.1 ± 128.8 194.5 ± 52.6partnerships and open source drug discovery present great
opportunities to screen more compounds for their anti-
schistosomal activities, but to take advantage of them, ef-
fective, inexpensive and practical in vitro methods are
required.
The aim of this research was to study a plethora of
fluorescent or luminescent viability and cytotoxicity
markers with various modes of action. In doing so, our
hope was to develop a simple, novel and automated
high-throughput in vitro drug sensitivity assay, as well as
to elucidate types of colorimetric markers that are suit-
able for larval helminth screens.nt® compared to microscopic values
Vybrant®
IC50 Microscopic
Readout (μM)
IC50 SpectraMax
(μM)
IC50 Microscopic
Readout (μM)
1.3 ± 0.9 not calculable 2.4 ± 1.2
2.4 ± 1.3 7.9 ± 1.7 1.7 ± 0.3
87.7 ± 49.7 not calculable 20.3 ± 9.5
Table 3 CellTiter-Glo® and microscopic evaluation of a small
subset (n = 25) of an FDA-approved compound library. Values of
% reduced viability of compound-treated NTS relative to the
controls were based on average luminescence for CellTiter-Glo®
(subtracted from background) and on average viability scores
for the microscopic evaluation.
% reduced viability relative to controls
Compound CellTiter-Glo® Microscopic Evaluation
acemetacin 0 11.1
benzalkonium chloride 94.9 100
cefpodoxime proxetil 0 0
clofazimine 85.2 100
clofibric acid 0 0
docosanol 0 0
docusate sodium 0 0
ecamsule triethanolamine 0 0
eletriptan hydrobromide 0 0
etidronate disodium 0 0
flumazenil 0.5 0
lomerazine hydrochloride 78.6 100
methylbenzethonium chloride 84.5 100
nicardipine hydrochloride 76.8 88.9
perhexiline maleate 94.5 100
pipamperone 0 0
pipemidic acid 0 0
quinine ethyl carbonate 0 0
ritodrine hydrochloride 0 0
saccharin 0 0
spiramycin 0 0
sulpiride 0 0
tamoxifen citrate 85.4 100
teicoplanin 0 0
tetramizole hydrochloride 0 0
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LIVE/DEAD®, the signals tended to correlate well with
an increased concentration of NTS (live NTS for viabil-
ity markers and dead NTS for cytotoxicity markers).
Moreover, the signals were usually differential between
live and dead NTS for markers that reacted with NTS
components that could be found in the medium, exclud-
ing CytoTox-ONE™ for which the difference was not at
all significant. An issue for the markers that relied on
staining NTS themselves was that signals were usually
far too low to differentiate between live and dead NTS.
Indeed, for markers that stained DNA of membrane-
damaged NTS, only complete cell lysis would provide
sufficiently high fluorescence signals. Since no drug
completely lyses NTS, markers with this limitation could
not be considered for further testing. In the case ofLIVE/DEAD®, we attempted to increase the signal with a
higher concentration of NTS and a smaller surface area
to scan (using a 384-well plate), which was sufficient to
render the signals differential between live and dead
NTS (Additional file 4: Figure S2). However, the number
of NTS required (1000 NTS) to achieve this and to
negate the background noise is far too high to make for
a realistically higher-throughput assay.
The largest issue that prevented markers from pro-
ceeding to further tests was that the background signals
were far too high, meaning the S/B ratio could not
exceed 3:1, our minimum standard. Issues with back-
ground signals were briefly explored in separate studies
with culture medium (Additional file 5: Figure S3). The
medium type and the presence of phenol red in the
medium did tend to affect the signal, but this depended
on the fluorescence marker used. The most notable
impact on the signal, however, resulted from presence of
iFCS in the medium, where removing it altogether would
have the greatest impact on reducing background fluor-
escence. Nonetheless, previous studies have demon-
strated that this is not a realistic option if NTS are to
remain viable throughout the duration of a 24 or 72 hour
drug assay [27].
Despite the above-described obstacles, resazurin,
CellTiter-Glo® and Vybrant® could be tested in a drug-
response assay. While a read-out with resazurin did not
correlate at all with microscopic findings (signals were
not differential enough to produce a curve), IC50 values
could be generated using CellTiter-Glo® and Vybrant®
that were close to the microscopic values for meflo-
quine. However, assays with Vybrant® could not produce
a curve for oxamniquine. No marker gave signals that
could be used to generate an IC50 value for praziquantel.
In the case of oxamniquine, the not entirely reprodu-
cible IC50 values are not altogether surprising since it is
not highly active in vitro and even microscopic evaluations
yield highly variable IC50 values. In contrast, microscopic
evaluations for praziquantel usually do result in a typical
dose–response curve. The lack of a dose–response rela-
tionship for praziquantel on NTS was observed also in
previous studies using fluorescence/luminescent markers
[9, 11, 18], and also when isothermal microcalorimetry
was used [14]. It has been suggested that this is because
praziquantel does not induce NTS death, which is true,
but it does very severely damage them and reduce their
motility, which should be reflected by reduced signals in
such markers. It is therefore conceivable that while prazi-
quantel does induce extensive damage, it also results in
high enzyme or ion channel activity, which interacts with
the viability markers and produces high signals.
Our comprehensive overview and studies are placed in
context of previous studies with fluorescence and lumines-
cence based NTS viability assays. Because of the Alamar
Panic et al. Parasites & Vectors  (2015) 8:624 Page 11 of 12Blue® experiments conducted by Mansour et al., [11] and
resazurin experiments with S. haematobium [23] that did
not yield promising results at the level of drug assay applic-
ability, we did not expect resazurin to perform well as a
marker and this was corroborated in our study. Our results
mirror those of Mansour et al. [11], where the signal-to-
NTS concentration tests shows promising results (albeit
only after 24 hours of incubation with the marker), but the
resazurin marker failed to generate dose-dependent viability
curves and to distinguish between live and dead NTS after
72 hours of drug exposure.
The fluorescein diacetate/ propidium iodide assay pub-
lished by Peak et al. is novel in that a duplex assay allows
for simultaneous assessment of viability and cytotoxicity
for S. mansoni adults and NTS [16]. The LIVE/DEAD®
viability/cytotoxicity kit assay tested in our study functions
in much the same way. Although Peak and colleagues had
better success in obtaining concordant signals from both
dyes, the fundamental issue with such markers in the end
is the high number of NTS required to assess viability in a
drug sensitivity assay, which reduces their throughput.
Indeed, Lalli et al. [18] showed in their study that
CellTiter-Glo® provides a far more sensitive assessment of
parasite viability and, considering that it measures ATP
production (which is theoretically abundant) after all the
NTS have been completely lysed by the reagent, this is not
surprising. In our study we also showed that CellTiter-Glo®
can be used to assess drug dose–response effects. Further-
more, a screen of a 25 compound subset of an FDA-
approved library showed 100 % correspondence between
microscopic evaluation and CellTiter-Glo® with regards to
hit identification, though all the active drugs in this screen
were completely schistocidal.
In contrast to the study by Lalli and colleagues [18], we
did see that if one wants to include compounds that dam-
age but may not necessarily kill the worm as hits, the assay
becomes less sensitive (as was shown with, for example,
praziquantel). This lack of sensitivity could be due to vari-
ability in NTS concentration- if a well contains 100 NTS
+/− 20 NTS, this already presents +/−20 % deviation in
NTS concentration and in corresponding signal. Large
signal variability might, therefore, impede the measurement
of fine gradients of reduced viability. This might be the
reason for large amounts of NTS used in previous studies
[16] or why Lalli and colleagues [18] used a multi-drop
sorter to dispense a more specific number of worms within
the assay. Thus for a sensitive marker-based assay, much
care needs to be undertaken to reduce NTS number
variability.
Conclusion
In summary, by testing a myriad of colorimetric markers
with diverse mechanisms of action, we conclude that
due to large fluctuations in signals, likely due to lownumbers of NTS that are sensitive to variation in NTS
concentration and viability, and high background noise,
it is difficult to develop a simple, cheap “just add” colori-
metric marker-based drug assay for the larval stage of
S. mansoni. Markers that stain NTS themselves require
a very large number of worms, and markers that assess
elements spilled into the medium may require either a
very specific number of worms or the removal of the
assay supernatant in order to yield high and uniform
signals. We could, however, confirm that CellTiter-Glo®
may be used as a pre-screening tool in determining live
and dead NTS in single drug concentration and potentially
in dose–response assays.
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